Skip to content

BBNX BBNX Return on equity

Return on equity at other companies

Insulet logo
InsuletPODD
23%-14.9pp
Tandem Diabetes Care logo
Tandem Diabetes CareTNDM
-65.7%-14.7pp
Medtronic logo
MedtronicMDT
9.8%+0.4pp
AdaptHealth logo
AdaptHealthAHCO
-5.2%-10.8pp
Halozyme Therapeutics logo
Halozyme TherapeuticsHALO
124.5%+12.7pp

Other financials

Income statement

See full
Revenue$27.6M+56.6%
Gross profit$16.4M+83.2%
Operating income-$24.3M-30.2%
Net income-$21.9M+23.6%
EPS (diluted)-$0.49+47.3%

Balance sheet

See full
Cash & equivalents$30.2M-28.9%
Total debt$6.9M-0.9%
Total equity$271.2M-13.5%
Total assets$304.4M-9.9%

Cash flow

See full
Operating cash flow-$23.8M-19.3%
CapEx$1.4M+314%
Free cash flow-$25.2M-24.1%

Valuation

See full
Market cap$708.98M-8.6%
Enterprise value$685.68M
P/S6.4×

Profitability

See full
Gross margin57.2%+3.2pp
Operating margin-70.1%-6.4pp
Net margin-60.3%-17.4pp
FCF margin-55.4%-14.3pp

Returns & leverage

See full
Debt / equity0.0×
Current ratio10.7×-5.2×

Where this comes from

Calculated from BBNX’s reported figures.

Based on trailing twelve months.

The official record: BBNX’s 10-Q, filed April 21, 2026, on SEC EDGAR. View the filing →

Ask your AI about BBNX's return on equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is BBNX's return on equity?
BBNX (BBNX) reported return on equity of -22.7% in Q1 2026.
What does return on equity mean?
Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.